Navigation Links
DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Date:3/31/2008

Completion of Target Enrollment Expected in Fourth Quarter

BERKELEY HEIGHTS, N.J., March 31 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the Data Safety Monitoring Board (DSMB) for AGENDA, a Phase 3 trial of Genasense (oblimersen sodium) Injection, which is the Company's lead oncology product, has recommended that the trial be continued as originally planned after initial review of blinded safety data from the study.

AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival.

At the end of the first quarter, the trial had accrued approximately 50 patients with approximately 60% of planned investigative sites having been initiated. Countries with sites currently open for enrollment include the U.S., Canada, Australia, France, Germany, Austria, and the Czech Republic. The trial is planned to open at approximately 90 sites worldwide, and most remaining sites are expected to initiate within the next 30 days. Target accrual of 300 patients is expected to complete in the fourth quarter of 2008, with initial data expected shortly thereafter.

"Investigator enthusiasm for AGENDA is quite high, and we are currently recruiting at our expected rate," said Dr. Loretta M. Itri, M.D., Genta's President, Pharmaceutical Development. "We believe the current rate, combin
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
2. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
3. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
4. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
5. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
6. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
8. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
11. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery ... report financial results for the first quarter fiscal year ... scheduled a conference call that same day, Thursday, November ... results. Interested parties can access the ...
(Date:10/30/2014)... WARSAW, Ind. , Oct. 30, 2014  Zimmer ... ZMH) today announced the future executive leadership team and ... of the Biomet transaction.  Zimmer also announced that the ... brands and will be named Zimmer Biomet, with the ... company following the closing of the merger.  The future ...
(Date:10/30/2014)... NEW YORK , Oct. 30, 2014  The ... United States is growing steadily, thanks to ... years, as a result of the economic downturn, retail ... was a year of opportunities, as the number of ... market researcher,s report, Retail Clinics Market Overview and ...
Breaking Medicine Technology:Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3
... Calif., April 29, 2011 First Quarter ... by 321 institutions, up from 239 in Q4 2010 ... revenue Operational focus enables lower planned expense growth in ... by Astellas NGX-1998 Phase 2 clinical trial continues in ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... cancers and infectious diseases, announced today that the company will ... Securities Research Conference San Francisco, CA, May 9-11, 2011 ... Dr. J. Joseph Kim, Ph.D., President & CEO May ...
Cached Medicine Technology:NeurogesX Reports First Quarter 2011 Results 2NeurogesX Reports First Quarter 2011 Results 3NeurogesX Reports First Quarter 2011 Results 4NeurogesX Reports First Quarter 2011 Results 5NeurogesX Reports First Quarter 2011 Results 6NeurogesX Reports First Quarter 2011 Results 7NeurogesX Reports First Quarter 2011 Results 8Inovio Pharmaceuticals to Present at Investor Conferences 2Inovio Pharmaceuticals to Present at Investor Conferences 3Inovio Pharmaceuticals to Present at Investor Conferences 4
(Date:10/30/2014)... Thompson HealthDay Reporter WEDNESDAY, ... Liberia -- one of three West African nations ravaged by ... said Wednesday. Dr. Bruce Aylward, WHO,s assistant director general, ... in Liberia and no increase in laboratory-confirmed cases. He said ... the epidemic may be making some progress, The New ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Global prebiotics ... 2020, according to a new study by Grand View ... surging demand for sugar and fat free products owing ... the demand for prebiotics over the forecast period. , ... , Food & beverage was the largest application ...
(Date:10/30/2014)... The annual meeting of The ... close on Saturday, October 18th, marking the end of ... 1989. NAMS is North America’s leading non-profit organization dedicated ... all women during midlife and beyond through an understanding ... and thought leaders from fields as varied as gynecology, ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Scientists who used stem ... say their breakthrough could provide a new way to ... diseases. The team used human pluripotent stem cells ... the body -- to grow the functional miniature stomachs, ... a major cause of ulcers and stomach cancer. ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Eating a low-carb, high-fat ... treat, according to new research. A review ... Atkins diet, that focuses on foods like bacon, eggs, ... reduce seizures in adults whose condition doesn,t improve with ... percent of people with epilepsy whose seizures are not ...
Breaking Medicine News(10 mins):Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... stereotypes; Today’s parents boast about the numerous classes kids attend ... many talents they possess. Competitive parents in their quest for ... often smother their children with an over-dose of love and ... play stations, and game boys… and Oh boy, the kid ...
... in Bahrain to receive urgently needed medical treatment.// ... as part of an agreement with the World Health Organisation ... a call to help fund treatment for seriously ill Iraqi ... head of the newly established Organisation for Culturing and Care ...
... sick with the dengue virus Monday with 56 fresh cases ... 941, and the Delhi government called an// urgent meeting to ... the All India Institute of Medical Sciences (AIIMS) reported 41, ... ,Of the 941 infected with the mosquito-borne virus, around ...
... are literate enough to understand the ill effects of tobacco, ... forms making them the most cancer// prone in the country. ... (NFHS) shows more than 22 percent Mizo women smoked against ... Ralte, principal investigator of the state's Tobacco Cessation Centre. ...
... watch shaky images recorded by an unsteadily held camera, one ... brain //restores an almost continuous shaky video stream from our ... also into consideration our bodies which is in constant motion ... the Salk Institute for Biological Studies have found that the ...
... happy to come away from any physicians chamber with ... medicines, as routinely done, would it be beneficial to ... A researcher in the Lipid Metabolism Laboratory at the ... Research Center on Aging (USDA HNRCA) at Tufts University, ...
Cached Medicine News:Health News:56 New Dengue Cases; Delhi Govt. to Review Situation 2Health News:Mizoram Women Under the Grip of Tobacco 2Health News:Perception Stabilized – Thanks to Your Brains 2Health News:Perception Stabilized – Thanks to Your Brains 3Health News:Exercise to be Prescribed for Robust Health in Elderly 2
The DSL-05-10-VZM Varicella Zoster IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Varicella Zoster Virus in human serum. This as...
Inquire...
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma....
... is comprised of the TEG analyzer and the ... picture of the formation and dissolution of the ... two systems. ,Haemoscope's TEG analyzer is the only ... the reliable and proven model developed by Prof. ...
Medicine Products: